Considerations for planning COVID-19 treatment services in humanitarian responses.
Africa
COVID-19
COVID-19 treatment service delivery
Coronavirus
Crisis
Fragile
Humanitarian
Low-income
SARS-CoV-2
Treatment
Journal
Conflict and health
ISSN: 1752-1505
Titre abrégé: Confl Health
Pays: England
ID NLM: 101286573
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
06
2020
accepted:
10
11
2020
entrez:
30
11
2020
pubmed:
1
12
2020
medline:
1
12
2020
Statut:
epublish
Résumé
The COVID-19 pandemic has the potential to cause high morbidity and mortality in crisis-affected populations. Delivering COVID-19 treatment services in crisis settings will likely entail complex trade-offs between offering services of clinical benefit and minimising risks of nosocomial infection, while allocating resources appropriately and safeguarding other essential services. This paper outlines considerations for humanitarian actors planning COVID-19 treatment services where vaccination is not yet widely available. We suggest key decision-making considerations: allocation of resources to COVID-19 treatment services and the design of clinical services should be based on community preferences, likely opportunity costs, and a clearly articulated package of care across different health system levels. Moreover, appropriate service planning requires information on the expected COVID-19 burden and the resilience of the health system. We explore COVID-19 treatment service options at the patient level (diagnosis, management, location and level of treatment) and measures to reduce nosocomial transmission (cohorting patients, protecting healthcare workers). Lastly, we propose key indicators for monitoring COVID-19 health services.
Identifiants
pubmed: 33250932
doi: 10.1186/s13031-020-00325-6
pii: 325
pmc: PMC7686825
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors do not report any competing interests.
Références
Lancet Glob Health. 2015 Aug;3(8):e439-e440
pubmed: 26163833
Lancet Glob Health. 2020 Oct;8(10):e1264-e1272
pubmed: 32687792
Open Forum Infect Dis. 2015 Dec 09;3(1):ofv192
pubmed: 26788546
Emerg Infect Dis. 2016 Mar;22(3):433-41
pubmed: 26886846
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
BMC Int Health Hum Rights. 2017 Jul 18;17(1):18
pubmed: 28720089
Occup Environ Med. 2020 May;77(5):281-282
pubmed: 32238444
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 32198275
Emerg Infect Dis. 2006 Aug;12(8):1238-41
pubmed: 16965703
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Health Policy Plan. 2020 Mar 1;35(2):210-218
pubmed: 31697373
Lancet Respir Med. 2020 Jun;8(6):e43
pubmed: 32333858
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Afr J Emerg Med. 2020 Sep;10(3):103-104
pubmed: 32837875
Confl Health. 2020 Jul 31;14:54
pubmed: 32754225
BMJ Glob Health. 2020 Jun;5(6):
pubmed: 32503889
BMC Med. 2020 Oct 14;18(1):324
pubmed: 33050951
World J Emerg Surg. 2020 Apr 9;15(1):26
pubmed: 32272957
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32513784